Time-Limited Therapy with Belatacept in Kidney Transplant Recipients.

ABSTRACT:

Introduction

In kidney transplant recipients, belatacept is usually pursued indefinitely after it has been started. In the setting of the belatacept shortage and after having evaluated the benefit-risk ratio, we established a strategy consisting of time-limited belatacept therapy/transient calcineurin inhibitor withdrawal, whose results are analyzed in that study.

Methods

We considered all the kidney transplant recipients that had been switched from conventional immunosuppressive therapy to belatacept and then for whom belatacept has been withdrawn intentionally. Furthermore, in the first 8 patients, we assessed changes in peripheral blood mononuclear cells (PBMC) transcriptome using RNAseq before and 3 months after belatacept withdrawal.

Results

Over the study period

SUBMITTER: Letellier T 

PROVIDER: S-EPMC9181670 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature